Immix Biopharma Inc. has released a presentation highlighting the significant unmet need in the treatment of relapsed/refractory AL amyloidosis. According to the data shared, approximately 38,500 patients in the U.S. face limited treatment options, with no FDA-approved drugs currently available for this condition. The presentation outlines the challenges associated with current standards of care, noting low complete response rates and significant patient morbidity. Immix Biopharma’s investigational therapy, NXC-201, is designed to target BCMA receptors on plasma cells, aiming to eliminate the source of toxic light chains that cause organ damage in AL amyloidosis. Clinical data from recent studies were included in the presentation. You can access the full presentation through the link below.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Immix Biopharma Inc. published the original content used to generate this news brief on February 04, 2026, and is solely responsible for the information contained therein.